BioPharmSignal logoBioPharmSignal

Biotech News

Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference

Disc Medicine (IRON)Disc MedicineConference / presentation

WATERTOWN, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John

Related news

RIGLRigel Pharmaceuticals2026-01-07 13:05 EST

Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference

SNDXSyndax Pharmaceuticals2026-01-12 12:00 EST

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

RCKTRocket Pharmaceuticals2026-01-05 12:00 EST

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

SNDXSyndax Pharmaceuticals2026-01-05 12:00 EST

Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

RIGLRigel Pharmaceuticals2026-05-27 12:05 EST

Rigel to Present at the Jefferies Global Healthcare Conference

SLNSilence Therapeutics2021-11-11 12:00 EST

Silence Therapeutics to Present at Jefferies London Healthcare Conference

GERNGeron2026-06-01 12:00 EST

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

GERNGeron2026-04-06 12:00 EST

Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference

RCKTRocket Pharmaceuticals2025-11-25 12:00 EST

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

View all latest news

Disc Medicine

Hematology Drug Development Disc Medicine develops therapies for serious hematologic diseases by targeting pathways involved in heme biosynthesis and iron regulation. Its portfolio addresses both rare red-blood-cell disorders and anemia associated with chronic disease. Bitopertin in EPP Bitopertin is being evaluated in the Phase 3 APOLLO...

Recent company news

IRONDisc Medicine2026-07-30 12:30 EST

Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update

IRONDisc Medicine2026-06-12 12:30 EST

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

IRONDisc Medicine2026-06-09 12:30 EST

Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria

IRONDisc Medicine2026-06-02 12:00 EST

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

IRONDisc Medicine2026-06-01 12:30 EST

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

Stock data

Close
77.44 USD
Market cap
2.6B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States